TWST · XBRL financial data

Twist Bioscience financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (TWST's year ends in late September)

In millions of dollars	Q4 FY23Sep 30, 2023	Q1 FY24Dec 31, 2023	Q2 FY24Mar 31, 2024	Q3 FY24Jun 30, 2024	Q4 FY24Sep 30, 2024	Q1 FY25Dec 31, 2024	Q2 FY25Mar 31, 2025	Q3 FY25Jun 30, 2025	Q4 FY25Sep 30, 2025	Q1 FY26Dec 31, 2025	Q2 FY26Mar 31, 2026	Q3 FY26Jun 30, 2026
Cost of revenue	42*	43	44	46	46*	46	47	45	48*	50	54	56
Research and development	24*	23	24	22	21*	21	24	18	17*	17	20	18
Selling, general and administrative	47*	53	56	57	53*	56	64	63	64*	70	76	81
Operating income (loss)	(50)*	(47)	(49)	(89)	(36)*	(35)	(42)	(30)	(30)*	(33)	(46)	(36)
Interest income	4*	4	4	4	4*	3	3	3	3*	2	2	2
Interest expense	0*	0	0	0	0*	0	0	—	—	—	—	—
Other income (expense)	(0)*	(0)	(0)	(0)	(2)*	(0)	(0)	(1)	0*	0	0	0
Income tax expense (benefit)	(0)*	0	0	0	(0)*	0	0	0	0*	0	0	0
Net income (loss)	(46)*	(43)	(45)	(86)	(35)*	(32)	(39)	20	(27)*	(31)	(44)	(35)
Earnings per share, basic USD per share	(0.81)*	(0.75)	(0.79)	(1.47)	(0.59)*	(0.53)	(0.66)	0.34	(0.45)*	(0.50)	(0.71)	(0.56)
Earnings per share, diluted USD per share	(0.81)*	(0.75)	(0.79)	(1.47)	(0.59)*	(0.53)	(0.66)	0.33	(0.46)*	(0.50)	(0.71)	(0.56)
Weighted average shares, basic millions of shares	57*	57	58	58	59*	59	60	60	60*	61	62	62
Weighted average shares, diluted millions of shares	57*	57	58	58	59*	59	60	61	59*	61	62	62

Fiscal quarters (TWST's year ends in late September)

In millions of dollars	Q4 FY23Sep 30, 2023	Q1 FY24Dec 31, 2023	Q2 FY24Mar 31, 2024	Q3 FY24Jun 30, 2024	Q4 FY24Sep 30, 2024	Q1 FY25Dec 31, 2024	Q2 FY25Mar 31, 2025	Q3 FY25Jun 30, 2025	Q4 FY25Sep 30, 2025	Q1 FY26Dec 31, 2025	Q2 FY26Mar 31, 2026	Q3 FY26Jun 30, 2026
Cash and cash equivalents	286	266	243	239	226	221	210	201	183	149	123	117
Short-term investments	50	45	50	50	50	49	47	49	49	49	49	49
Accounts receivable	44	35	36	32	35	39	50	50	57	50	64	65
Inventory	32	31	30	28	24	24	21	26	28	33	34	35
Prepaid and other current assets	12	13	12	12	11	12	10	13	15	23	54	54
Total current assets	424	390	372	362	347	345	338	340	333	304	323	321
Property and equipment, net	132	126	121	106	103	101	97	95	102	105	111	112
Right-of-use asset	72	69	64	61	59	56	54	52	49	72	71	69
Goodwill	86	86	86	86	86	86	86	82	82	82	82	82
Total assets	776	733	703	638	614	609	596	644	642	638	676	672
Accounts payable	14	9	8	7	2	8	8	12	11	12	15	17
Accrued liabilities	11	14	15	15	15	20	20	20	23	23	25	20
Total current liabilities	73	65	67	74	71	70	75	87	91	80	120	120
Lease liability, non-current	79	77	75	73	70	68	65	63	62	86	85	85
Total liabilities	153	143	143	147	142	153	156	165	169	182	221	227
Accumulated deficit	(1,033)	(1,076)	(1,122)	(1,207)	(1,242)	(1,274)	(1,313)	(1,292)	(1,320)	(1,350)	(1,394)	(1,429)
Total stockholders' equity	623	590	560	491	473	456	440	478	473	456	455	446
Total liabilities and equity	776	733	703	638	614	609	596	644	642	638	676	672
Common shares outstanding (cover page) millions of shares	58	58	58	59	59	60	60	60	61	61	62	63

Fiscal quarters (TWST's year ends in late September)

In millions of dollars	Q4 FY23Sep 30, 2023	Q1 FY24Dec 31, 2023	Q2 FY24Mar 31, 2024	Q3 FY24Jun 30, 2024	Q4 FY24Sep 30, 2024	Q1 FY25Dec 31, 2024	Q2 FY25Mar 31, 2025	Q3 FY25Jun 30, 2025	Q4 FY25Sep 30, 2025	Q1 FY26Dec 31, 2025	Q2 FY26Mar 31, 2026	Q3 FY26Jun 30, 2026
Net income (loss)	(46)*	(43)	(45)	(86)	(35)*	(32)	(39)	20	(27)*	(31)	(44)	(35)
Stock-based compensation	12*	11	14*	14*	12*	12	20*	16*	16*	13	19*	18*
Depreciation and amortization	9*	8	8*	8*	7*	6	6*	6*	6*	6	6*	7*
Net cash from operating activities	(21)*	(23)	(19)*	(6)*	(15)*	(21)	(13)*	(1)*	(12)*	(25)	(18)*	1*
Purchases of property and equipment	2*	2	1*	1*	2*	2	4*	9*	12*	10	8*	10*
Net cash from investing activities	(2)*	4	(5)*	(1)*	(1)*	(2)	(1)*	(9)*	(12)*	(10)	(13)*	(10)*
Repayments of long-term debt	0*	—	—	—	year only	—	—	—	—	—	—	—
Net cash from financing activities	0*	(1)	2*	3*	4*	18	3*	2*	6*	0	4*	4*
Net change in cash	(23)*	(20)	(23)*	(4)*	(13)*	(5)	(11)*	(9)*	(18)*	(34)	(26)*	(5)*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Twist Bioscience	117	not reported	1.1*	62.7M	—	Q3 FY26 10-QJun 30, 2026
Acadia Pharmaceuticals	385	308	101*	172.3M	—	Q2 FY26 10-QJun 30, 2026
Xenon Pharmaceuticals	120	not reported	(95)*	96.8M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Summit Therapeutics	419	not reported	(141)*	797.7M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Cytokinetics	255	29	(160)*	139.0M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
TG Therapeutics	483	240	39*	153.1M	—	Q2 FY26 10-QJun 30, 2026
Catalyst Pharmaceuticals	756	149	60	122.4M	—	Q1 FY26 10-QMar 31, 2026
Vericel	125	77	16*	51.2M	—	Q2 FY26 10-QJun 30, 2026
Recursion Pharmaceuticals	550	19	(77)*	622.8M	6.2 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.